Replies to post #484719 on Anavex Life Sciences Corp (AVXL)

[dia76ca]

The new patent shows the wide range of blarcamesines application!
"The neurological disease may be selected from cognitive impairment, Lewy body dementia, stroke, traumatic brain injury, infections, spinal cord injury, Alzheimer’s disease, Parkinson’s disease, dementia, Huntington’s disease, Amyotrophic lateral sclerosis, Prion disease, Rett Syndrome, Fragile X Syndrome, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith -Magenis syndrome, multiple sclerosis, Fronto-temporal dementia, motor neuron disease (MND), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), autism spectrum disorder, schizophrenia, post-traumatic stress disorder (PTSD), and any combination thereof."

[falconer66a]

The New Anavex Patent

Stopping Brain Shrinkage

I just did a quick read-through of the new Anavex patent, TREATMENT AND PREVENTION OF CEREBRAL ATROPHY. A thorough description of the patent would take about 10 pages, with commentaries on each paragraph. But everyone holding or contemplating the taking of an AVXL position should take the time to read through the entire patent application. Even if you are not familiar with the medical terminology, you will discern that this patent is very important.

It shows that Anavex’s sigma-1 receptor agonists are able to actually prevent or stop the shrinkage, atrophy, of various brain tissues, which is associated with or caused by either simple aging or any of the multitude of diseases and pathologies listed in the patent.

Brain atrophy is a major health problem, occurring both from general aging processes and from the many diseases listed in the patent. A diagnosis of a shrinking brain, as definitely revealed by medical imaging, is profoundly ominous. Presently, there is no effective treatment. The brain will continue to wither and lose function, with a lethal outcome.

As in all of the other diseases where blarcamesine has been clinically tested, the use of the drug for prophylaxis or treatment of brain atrophy will be profoundly safe. No disqualifying adverse events (“side effects”).

The drug can be conveniently administered per os, as a swallowed pill.

There is now the firm prospect that the Anavex drug blarcamesine will eventually be approved for sale and as a safe, efficacious therapy for the multitude of diseases and conditions that produce atrophy, shrinkage, of the brain. There is no other drug that can do this as safely, effectively, and inexpensively as can blarcamesine. Once approved, the Anavex drug will become an SOC, a standard of care drug; here for brain atrophy. An effective new medical treatment.

As mentioned in the patent, after the age of forty, human brains begin to slowly shrink, a normal aging process. What, then, do you suppose will be the outcome when middle-aged people get prescribed daily doses of a bit of blarcamesine, to prophylactically slow or delay this normal brain shrinkage? Might it be supposed that people will then live longer, with minimal loss of cognition in their later years?

Once again, the propitious blarcamesine prophylaxis factor.

[kund]

There is no such thing as a worldwide patent. Misleading has to file separate applications in each of the countries mentioned in the WO application.

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)